716 related articles for article (PubMed ID: 32387320)
21. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
22. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
27. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Yang X; Yu Y; Xu J; Shu H; Xia J; Liu H; Wu Y; Zhang L; Yu Z; Fang M; Yu T; Wang Y; Pan S; Zou X; Yuan S; Shang Y
Lancet Respir Med; 2020 May; 8(5):475-481. PubMed ID: 32105632
[TBL] [Abstract][Full Text] [Related]
28. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study".
Entrenas Castillo M; Entrenas Costa LM; Vaquero Barrios JM; Alcalá Díaz JF; López Miranda J; Bouillon R; Quesada Gomez JM
J Steroid Biochem Mol Biol; 2020 Oct; 203():105751. PubMed ID: 32871238
[TBL] [Abstract][Full Text] [Related]
29. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.
de Cáceres C; Martínez R; Bachiller P; Marín L; García JM
Pharmacol Rep; 2020 Dec; 72(6):1529-1537. PubMed ID: 33165762
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital.
Turcotte JJ; Meisenberg BR; MacDonald JH; Menon N; Fowler MB; West M; Rhule J; Qureshi SS; MacDonald EB
PLoS One; 2020; 15(8):e0237558. PubMed ID: 32785285
[TBL] [Abstract][Full Text] [Related]
32. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.
Roncon L; Zuin M; Rigatelli G; Zuliani G
J Clin Virol; 2020 Jun; 127():104354. PubMed ID: 32305882
[TBL] [Abstract][Full Text] [Related]
33. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
[TBL] [Abstract][Full Text] [Related]
34. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
García-Suárez J; de la Cruz J; Cedillo Á; Llamas P; Duarte R; Jiménez-Yuste V; Hernández-Rivas JÁ; Gil-Manso R; Kwon M; Sánchez-Godoy P; Martínez-Barranco P; Colás-Lahuerta B; Herrera P; Benito-Parra L; Alegre A; Velasco A; Matilla A; Aláez-Usón MC; Martos-Martínez R; Martínez-Chamorro C; Susana-Quiroz K; Del Campo JF; de la Fuente A; Herráez R; Pascual A; Gómez E; Pérez-Oteyza J; Ruiz E; Alonso A; González-Medina J; Martín-Buitrago LN; Canales M; González-Gascón I; Vicente-Ayuso MC; Valenciano S; Roa MG; Monteliu PE; López-Jiménez J; Escobar CE; Ortiz-Martín J; Diez-Martin JL; Martinez-Lopez J;
J Hematol Oncol; 2020 Oct; 13(1):133. PubMed ID: 33032660
[TBL] [Abstract][Full Text] [Related]
35. Bloodstream infections in critically ill patients with COVID-19.
Giacobbe DR; Battaglini D; Ball L; Brunetti I; Bruzzone B; Codda G; Crea F; De Maria A; Dentone C; Di Biagio A; Icardi G; Magnasco L; Marchese A; Mikulska M; Orsi A; Patroniti N; Robba C; Signori A; Taramasso L; Vena A; Pelosi P; Bassetti M
Eur J Clin Invest; 2020 Oct; 50(10):e13319. PubMed ID: 32535894
[TBL] [Abstract][Full Text] [Related]
36. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
[TBL] [Abstract][Full Text] [Related]
37. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.
Marfella R; Paolisso P; Sardu C; Bergamaschi L; D'Angelo EC; Barbieri M; Rizzo MR; Messina V; Maggi P; Coppola N; Pizzi C; Biffi M; Viale P; Galié N; Paolisso G
Diabetes Metab; 2020 Oct; 46(5):403-405. PubMed ID: 32447102
[TBL] [Abstract][Full Text] [Related]
38. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V; Birlutiu RM; Chicea L
Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.
Barrasa H; Rello J; Tejada S; Martín A; Balziskueta G; Vinuesa C; Fernández-Miret B; Villagra A; Vallejo A; San Sebastián A; Cabañes S; Iribarren S; Fonseca F; Maynar J;
Anaesth Crit Care Pain Med; 2020 Oct; 39(5):553-561. PubMed ID: 32278670
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region.
Majmundar M; Kansara T; Lenik JM; Park H; Ghosh K; Doshi R; Shah P; Kumar A; Amin H; Chaudhari S; Habtes I
PLoS One; 2020; 15(9):e0238827. PubMed ID: 32903258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]